Treatment with Romosozumab, a neutralizing antibody against Sclerostin, increases bone mass by uncoupling the transient activation of osteoblasts with the sustained inhibition of osteoclast activity in osteoporosis patients [10]. This evidence concerns the gene SOST and osteoporosis.